ARCHIVES

FDA Advisory Committee Recommends Approval Of Ifosfamide as Third Line Therapy For Testicular Cancer

This article is from The Cancer Letter archive.

Vol. 14 No. 18 | April 29, 1988

Download PDF Visit The Full Archive

Related Articles

Reexamine Mandates, Samuels Suggests

February 17, 1984

Economic Analysis Finds Erlotinib Marginally Cost-Effective For NSCLC

February 26, 2010

Sandra Swain at ASCO 2013: Let’s Focus on Three Goals

June 7, 2013

Some NCI Responses To CCOP Letters Of Intent Missing; NCAB Debates Pediatric Issues

October 8, 1982

FDA News: Consolidation Plan Designed For Savings

June 5, 1998

Moloney Out As Viral Oncology Chief, Names “Acting Assistant Director” Of NCI By Upton

January 6, 1978